Advances in Cancer Immunotherapy™

All cancellations must be received in writing. You may fax your cancellation to +1 414-276-3349 or e-mail events@sitcancer.org. Requests must be made 3 weeks prior to the event. A $25 processing fee will be charged for all paid registration cancellations.

All refunds will be processed after the programs; you will receive an e-mail confirmation. No refunds will be granted if cancellation is received after the 3 weeks out date . Special considerations will be given for health or family emergencies if requested in writing to events@sitcancer.org no later than 14 business days after the last day of the programs.

SITC often employs the services of a professional photographer/videographer at SITC events to capture images and audiovisual (AV) recordings for use in society archival and promotional material. Your attendance at SITC events implies your permission for images and an AV recording captured to be used for purposes of SITC archival materials, promotional materials, and publications, and waives your rights for compensation or ownership of these images.

View the SITC Meeting Code of Conduct.

Complete these certified, interactive online courses to deepen your understanding of cancer immunotherapy and learn about the most recent FDA approvals in several diseases states and the latest guidelines on how to treat immune-related adverse events. Additional courses address how to overcome practical barriers to implementation, which are critical for helping your staff to help patients obtain reimbursement for immunotherapy. Each course is eligible for CME, CNE, CPE and/or MOC credits.

Online courses include links to the original trials, the latest FDA approvals, real-world case studies and questions to help deepen understanding and retention. There are also printable charts outlining best practices for treating immune-related adverse effects and links to the Cancer Immunotherapy Guidelines which can support decision-making.

Log in to the free ACI webinars to learn about new treatment approvals and emerging scientific data relating to clinical applications of cancer immunotherapy. Hosted by experts in the field, the webinars provide an opportunity to continue your learning from this ACI program and interact with faculty during a dedicated question-and-answer session.

On-Demand Webinar Recordings and Slides

• Advances in Cancer Immunotherapy^TM: Clinical Updates from ASCO 2021 (October 6, 2021)
• Advances in Cancer Immunotherapy™️ Webinar: Clinical Updates from ESMO Immuno-Oncology Congress 2020 (July 16, 2021)
• Advances in Cancer Immunotherapy™ Webinar: Clinical Updates from SITC 2020 (March 30, 2021)

Please note that the on-demand webinars are not available for continuing education credits.

• Overview of common approaches to cancer immunotherapy and their related mechanisms
• Timely updates on the latest clinical advances in the field, including data from recent scientific meetings and clinical trials
• Dedicated opportunities for clinicians to ask questions and receive direction on difficult cases
• Strategies for addressing the practical barriers to implementing immunotherapy (operations, reimbursement and management of emerging toxicities)

The ACI programs aim to reach practicing clinical oncologists, advanced practitioners, nurses, pharmacists, emergency physicians, and other allied health professionals who wish to learn the basic principles of cancer immunotherapy and the most up-to-date clinical data for these treatments, in a multitude of disease states/therapeutic areas, in order to inform and integrate into their own clinical practice. In-training oncologists and hospital administrators will also find the program beneficial.

• Sanjiv S. Agarwala, MD
  Temple University
• Christian Capitini, MD (Chair)
  University of Wisconsin Carbone Cancer Center
• Amber Cipriani, PharmD, BCOP, CPP
  UNC Healthcare
• Marianne Davies, DNP, MSN, RN, APRN, CNS-BC, ACNP-BC, AOCNP (Co-chair
  Yale School of Nursing
• Adi Diab, MD
  The University of Texas MD Anderson Cancer Center
• Isabella C. Glitza, MD, PhD
  The University of Texas MD Anderson Cancer Center
• Paul S. Jansson, MD, MS
  Harvard Medical School
  
• Lisa Kottschade, APRN, MSN, CNP
  Mayo Clinic
  
• Zihai Li, MD, PhD
  The Ohio State University
• Pradnya Patil, MD, FACP
  Cleveland Clinic Taussig Cancer Center
• Chrystal Paulos, PhD
  Emory University
• Mark Rubinstein, PhD
  Cleveland Clinic Taussig Cancer Center
• Raju Vaddepally, MD
  Yuma Regional Medical Center Cancer Center
• Yiping Yang, MD, PhD
  The Ohio State University
• Dan P. Zandberg, MD
  UPMC Hillman Cancer Center
• Lei Zheng, MD, PhD
  Johns Hopkins University School of Medicine

• Sanjiv S. Agarwala, MD (Chair)
  Temple University
• Christian Capitini, MD (Co-chair)
  University of Wisconsin Carbone Cancer Center
• Amber Cipriani, PharmD, BCOP, CPP
  UNC Healthcare
• Marianne Davies, DNP, MSN, RN, APRN, CNS-BC, ACNP-BC, AOCNP
  Yale School of Nursing
• Adi Diab, MD
  The University of Texas MD Anderson Cancer Center
• Sarah B. Dubbs, MD, FAAEM
  University of Maryland School of Medicine
• Isabella C. Glitza, MD, PhD
  The University of Texas MD Anderson Cancer Center
• Zihai Li, MD, PhD
  The Ohio State University
• Pradnya Patil, MD, FACP
  Cleveland Clinic Taussig Cancer Center
• Chrystal Paulos, PhD
  Emory University
• Mark Rubinstein, PhD
  Cleveland Clinic Taussig Cancer Center
• Yiping Yang, MD, PhD
  The Ohio State University
• Dan P. Zandberg, MD
  UPMC Hillman Cancer Center
• Lei Zheng, MD, PhD
  Johns Hopkins University School of Medicine